<h2>Mirum Pharmaceuticals：近期表现快照</h2>
<p>Mirum Pharmaceuticals (MIRM) 在今年表现强劲，吸引了关注，股价上涨约 31%，过去一年总回报约为 127%。</p>
<p>查看我们对 Mirum Pharmaceuticals 的最新分析。</p>
<p>在这段强劲的表现后，股价最近有所回落，最新收盘价为 102.19 美元，1 天股价回报下跌 8.3%，7 天股价回报下跌 4.6%。1 年总股东回报仍然非常可观，5 年总股东回报接近 5 倍。</p>
<p>如果你对罕见疾病的投资感兴趣，可以通过扫描 32 只医疗保健 AI 股票，了解其他相关动态。</p>
<p>目前 Mirum Pharmaceuticals 的估值约为 68 亿美元，且交易价格低于一些分析师的目标和内在估计，你不得不问：这是一只打折的罕见疾病股票，还是市场已经在定价未来的增长？</p>
<h2>最受欢迎的叙述：低估 21.2%</h2>
<p>在最新收盘价 102.19 美元与最受关注的公允价值估计约 129.73 美元相比，目前 Mirum Pharmaceuticals 的价格远低于这一叙述目标，该目标基于对未来收入增长、盈利能力和现金流的详细假设，折现率为 7.24%。</p>
<blockquote>
<p><em>多个晚期管线催化剂，包括未来 24 个月内的三项关键研究结果（VISTAS、VANTAGE、EXPAND）以及 II 期脆性 X 研究的启动，为进一步的产品标签扩展和新适应症推出奠定了基础，支撑未来收入多样化和潜在盈利加速。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>想知道为了维持这种估值需要什么样的收入曲线和利润率吗？这个叙述依赖于持续的两位数顶线扩张，从当前亏损到正盈利的明确路径，以及与更快增长行业更常见的前瞻性利润倍数。想看看这些动态如何结合在一起，以及市场将为这些未来盈利支付多少？</p>
<p><strong>结果：公允价值 129.73 美元（低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，如果关键注册试验未能如预期，或罕见疾病定价压力限制 Livmarli 和胆汁酸组合的收入潜力，这一叙述可能会迅速转变。</p>
<p>了解 Mirum Pharmaceuticals 叙述的关键风险。</p>
<h2>另一种看待估值的方法</h2>
<p>早期的公允价值观点在很大程度上依赖于详细的现金流和盈利预测。一个更简单的检查是使用当前的市销率 10.9 倍，与美国生物科技行业的 10.9 倍、同行的 11.5 倍和公允比率的 9.3 倍相比，这表明价格标签更高，若增长或定价假设放缓，容错空间较小。</p>
<p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="650" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2"/></p>
<p>NasdaqGM:MIRM 截至 2026 年 5 月的市销率</p>
<h2>下一步</h2>
<p>看到文章中既有强劲回报又有估值争论，检查基础数据、权衡潜在收益和风险，然后决定你对当前设置的舒适度，回顾 3 个关键收益和 2 个重要警示信号是明智的。</p>
<h2>寻找更多投资想法？</h2>
<p>不要止步于单一股票故事。通过筛选器扩展你的观察名单，获取关注质量、价值和韧性的股票想法。</p>
<ul>
<li>通过扫描 50 只高质量低估股票，寻找潜在的错误定价，这些股票结合了稳健的基本面和未完全反映其财务状况的价格。</li>
<li>通过审查 12 只高股息股票，增强你的收入流，这些股票强调了持久性。</li>
<li>通过检查 66 只低风险股票，减少投资组合的意外，这些公司具有更强的财务和风险韧性。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>并且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看你的总额</p>
<p>• 通过电子邮件或手机接收新的警示信号或风险提示</p>
<p>• 跟踪你股票的公允价值</p>
<p>免费试用演示投资组合</p>

MIRM

<p>Mirum Pharmaceuticals (MIRM) 今年表现强劲，股价上涨了 31%，但最近出现回调，收盘价为 102.19 美元，单日下跌 8.3%。分析师估计其公允价值为 129.73 美元，暗示该股票被低估。公司有多个晚期管线催化剂可能推动未来增长，但如果关键试验失利或面临价格压力，仍然存在风险</p>

<h2>Mirum Pharmaceuticals: recent performance snapshot</h2>
<div class="lb-trans"><h2>Mirum Pharmaceuticals：近期表现快照</h2>
</div><p>Mirum Pharmaceuticals (MIRM) has attracted attention after a strong year to date, with the stock up about 31% and a total return of roughly 127% over the past year.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals (MIRM) 在今年表现强劲，吸引了关注，股价上涨约 31%，过去一年总回报约为 127%。</p>
</div><p>See our latest analysis for Mirum Pharmaceuticals.</p>
<div class="lb-trans"><p>查看我们对 Mirum Pharmaceuticals 的最新分析。</p>
</div><p>After this strong run, the share price has recently cooled, with the latest close at $102.19, a 1 day share price return of down 8.3% and a 7 day share price return of down 4.6%. The 1 year total shareholder return remains very large and the 5 year total shareholder return sits near 5x.</p>
<div class="lb-trans"><p>在这段强劲的表现后，股价最近有所回落，最新收盘价为 102.19 美元，1 天股价回报下跌 8.3%，7 天股价回报下跌 4.6%。1 年总股东回报仍然非常可观，5 年总股东回报接近 5 倍。</p>
</div><p>If rare disease exposure has your attention, it can be useful to see what else is moving in healthcare by scanning 32 healthcare AI stocks</p>
<div class="lb-trans"><p>如果你对罕见疾病的投资感兴趣，可以通过扫描 32 只医疗保健 AI 股票，了解其他相关动态。</p>
</div><p>With Mirum Pharmaceuticals now valued at about US$6.8b and trading at a discount to some analyst targets and intrinsic estimates, you have to ask: is this a rare disease stock on sale, or is the market already pricing in future growth?</p>
<div class="lb-trans"><p>目前 Mirum Pharmaceuticals 的估值约为 68 亿美元，且交易价格低于一些分析师的目标和内在估计，你不得不问：这是一只打折的罕见疾病股票，还是市场已经在定价未来的增长？</p>
</div><h2>Most Popular Narrative: 21.2% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：低估 21.2%</h2>
</div><p>At a last close of $102.19 versus a most followed fair value estimate of about $129.73, the current Mirum Pharmaceuticals price sits well below that narrative target, which is built on detailed assumptions about future revenue growth, profitability and cash flows discounted at 7.24%.</p>
<div class="lb-trans"><p>在最新收盘价 102.19 美元与最受关注的公允价值估计约 129.73 美元相比，目前 Mirum Pharmaceuticals 的价格远低于这一叙述目标，该目标基于对未来收入增长、盈利能力和现金流的详细假设，折现率为 7.24%。</p>
</div><blockquote>
<p><em>Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>多个晚期管线催化剂，包括未来 24 个月内的三项关键研究结果（VISTAS、VANTAGE、EXPAND）以及 II 期脆性 X 研究的启动，为进一步的产品标签扩展和新适应症推出奠定了基础，支撑未来收入多样化和潜在盈利加速。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Curious what kind of revenue curve and margin profile would need to play out for this valuation to hold up? The narrative leans on sustained double digit top line expansion, a clear path from current losses into positive earnings, and a forward profit multiple more often associated with faster growing sectors. Want to see how those moving parts fit together and what the market would be asked to pay for those future earnings?</p>
<div class="lb-trans"><p>想知道为了维持这种估值需要什么样的收入曲线和利润率吗？这个叙述依赖于持续的两位数顶线扩张，从当前亏损到正盈利的明确路径，以及与更快增长行业更常见的前瞻性利润倍数。想看看这些动态如何结合在一起，以及市场将为这些未来盈利支付多少？</p>
</div><p><strong>Result: Fair Value of $129.73 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值 129.73 美元（低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, this narrative can quickly shift if key registrational trials disappoint, or if pressure on rare disease pricing limits Livmarli and bile acid portfolio revenue potential.</p>
<div class="lb-trans"><p>然而，如果关键注册试验未能如预期，或罕见疾病定价压力限制 Livmarli 和胆汁酸组合的收入潜力，这一叙述可能会迅速转变。</p>
</div><p>Find out about the key risks to this Mirum Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>了解 Mirum Pharmaceuticals 叙述的关键风险。</p>
</div><h2>Another way to look at the valuation</h2>
<div class="lb-trans"><h2>另一种看待估值的方法</h2>
</div><p>The earlier fair value view leans heavily on detailed cash flow and earnings forecasts. A simpler check uses the current P/S of 10.9x compared with the US Biotechs industry at 10.9x, peers at 11.5x and a fair ratio of 9.3x, which points to a richer price tag and less margin for error if growth or pricing assumptions soften.</p>
<div class="lb-trans"><p>早期的公允价值观点在很大程度上依赖于详细的现金流和盈利预测。一个更简单的检查是使用当前的市销率 10.9 倍，与美国生物科技行业的 10.9 倍、同行的 11.5 倍和公允比率的 9.3 倍相比，这表明价格标签更高，若增长或定价假设放缓，容错空间较小。</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE2" alt="" original-src="https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry?date=2026-05-16"/></p>
<p>NasdaqGM:MIRM P/S Ratio as at May 2026</p>
<div class="lb-trans"><p>NasdaqGM:MIRM 截至 2026 年 5 月的市销率</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>Seeing both strong returns and valuation debate in the article, it makes sense to check the underlying data, weigh the upside and the risks, and then decide how comfortable you are with the current setup by reviewing the 3 key rewards and 2 important warning signs</p>
<div class="lb-trans"><p>看到文章中既有强劲回报又有估值争论，检查基础数据、权衡潜在收益和风险，然后决定你对当前设置的舒适度，回顾 3 个关键收益和 2 个重要警示信号是明智的。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Do not stop with a single stock story. Broaden your watchlist with focused stock ideas sourced from screeners that highlight quality, value and resilience.</p>
<div class="lb-trans"><p>不要止步于单一股票故事。通过筛选器扩展你的观察名单，获取关注质量、价值和韧性的股票想法。</p>
</div><ul>
<li>Target potential mispricings by scanning 50 high quality undervalued stocks that combine solid fundamentals with prices that do not fully reflect their financial profile.</li>
<li>Strengthen your income stream by reviewing 12 dividend fortresses that pair higher yields with an emphasis on staying power.</li>
<li>Reduce portfolio surprises by checking 66 resilient stocks with low risk scores built around companies with more resilient financial and risk profiles.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描 50 只高质量低估股票，寻找潜在的错误定价，这些股票结合了稳健的基本面和未完全反映其财务状况的价格。</li>
<li>通过审查 12 只高股息股票，增强你的收入流，这些股票强调了持久性。</li>
<li>通过检查 66 只低风险股票，减少投资组合的意外，这些公司具有更强的财务和风险韧性。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>并且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看你的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警示信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪你股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

在经历了强劲的一年后，评估 Mirum Pharmaceuticals (MIRM) 的估值及其近期股价回调